Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 3/20 | 0.38 |
| ▸ | IDH1 | O75874 | 11/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 4/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25884356 | 0.74 | KDM4E (0.36) | — | |
| SCHEMBL25301262 | 0.73 | GFER (0.35) | — | |
| SCHEMBL25298684 | 0.71 | CHRM4 (0.37) | CHRM4IDH1CYP1A2CYP2D6IDH2 | |
| SCHEMBL25238790 | 0.68 | EHMT2 (0.48) | — | |
| SCHEMBL30971323 | 0.66 | CHRM4 (0.36) | CHRM4IDH1CYP1A2CYP2D6IDH2 | |
| SCHEMBL11985865 | 0.63 | KDM4E (0.36) | — | |
| SCHEMBL31127090 | 0.63 | IDH1 (0.40) | CHRM4IDH1CYP1A2CYP2D6 | |
| SCHEMBL21143828 | 0.63 | KCNN3 (0.55) | CYP1A2 | |
| SCHEMBL21143735 | 0.63 | IDH1 (0.40) | CHRM4IDH1CYP1A2CYP2D6 | |
| SCHEMBL20814430 | 0.62 | IDH1 (0.47) | CHRM4IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2025-09-02 | — | — | US | disclosed |
| EP-4452984-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | Molecure S.A. (PL) | 2024-10-30 | — | — | EP | disclosed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| WO-2023119233-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023119233-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | CHRM4 4675/4885IDH1 4075/4885CYP1A2 3846/4885 |
| US-12404279-B2 | Deubiquitinase inhibitors and methods of use thereof | USP7, USP28, USP1 | CHRM4 4675/4885IDH1 4075/4885CYP1A2 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.